Literature DB >> 9173912

Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain.

D T Stephenson1, C A Lemere, D J Selkoe, J A Clemens.   

Abstract

Phospholipase A2 (PLA2) is the key enzyme that initiates the arachidonic acid cascade, which leads to the generation of multiple eicosanoid products. Many of these products are believed to play an important role in the inflammatory process. Activation of PLA2 is observed under pathological conditions where inflammation is present. Cytosolic PLA2 (cPLA2) is activated by very low levels of calcium and is thought to control receptor-mediated eicosanoid production and to participate in intracellular signal transduction processes. In view of the presence of numerous inflammatory mediators and acute phase proteins in the Alzheimer's disease (AD) brain, localization of cPLA2 in AD brain was evaluated and compared to that observed in nonneurologically diseased controls. In this study, a monoclonal antibody raised against cPLA2 was used to immunostain tissue sections of human cerebral cortex. Five AD cases and six neurologically normal cases were evaluated in the occipital cortex and the cerebellum. Two of the AD cases were also examined in other cortical regions. Granular-like staining with anti-cPLA2 was found to be associated with astrocytes in the cortex of both control and AD cases. Colocalization with GFAP confirmed that cPLA2 immunoreactivity is associated almost exclusively with protoplasmic astrocytes. Staining was abolished when sections were labeled with antibody that had been preadsorbed with purified cPLA2. In AD brain, cPLA2 immunoreactive astrocytes were greater in number and more intensely stained than those in control cases. cPLA2 immunoreactivity was virtually absent in the cerebelium of AD and control cases, despite the presence in this region of diffuse amyloid in two AD cases and amyloid angiopathy in a third case. In the cortex, cPLA2 immunoreactive astrocytes were detected in regions that contained numerous A beta deposits. The finding of elevated levels of cPLA2 immunoreactivity in AD brain supports the hypothesis that there is an active inflammatory process occurring in AD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9173912     DOI: 10.1006/nbdi.1996.0005

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  67 in total

Review 1.  Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens.

Authors:  A A Farooqui; S I Rapoport; L A Horrocks
Journal:  Neurochem Res       Date:  1997-04       Impact factor: 3.996

Review 2.  Membrane biophysics and mechanics in Alzheimer's disease.

Authors:  Xiaoguang Yang; Sholpan Askarova; James C-M Lee
Journal:  Mol Neurobiol       Date:  2010-05-01       Impact factor: 5.590

3.  Phosphatidylcholine-specific phospholipase C regulates glutamate-induced nerve cell death.

Authors:  Y Li; P Maher; D Schubert
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

Review 4.  Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain.

Authors:  Kenneth I Strauss
Journal:  Brain Behav Immun       Date:  2007-11-08       Impact factor: 7.217

Review 5.  Cellular membrane fluidity in amyloid precursor protein processing.

Authors:  Xiaoguang Yang; Grace Y Sun; Gunter P Eckert; James C-M Lee
Journal:  Mol Neurobiol       Date:  2014-02-20       Impact factor: 5.590

6.  In silico identification of new genetic variations as potential risk factors for Alzheimer's disease in a microarray-oriented simulation.

Authors:  R R Lemos; C H Castelletti; J L Lima Filho; E T Marques; J R M Oliveira
Journal:  J Mol Neurosci       Date:  2009-03-17       Impact factor: 3.444

Review 7.  Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease.

Authors:  Evelin L Schaeffer; Orestes V Forlenza; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-10-14       Impact factor: 4.530

8.  Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Aβ42 Phagocytosis.

Authors:  Mingqin Zhu; Xiuzhe Wang; Erik Hjorth; Romain A Colas; Lisa Schroeder; Ann-Charlotte Granholm; Charles N Serhan; Marianne Schultzberg
Journal:  Mol Neurobiol       Date:  2015-12-09       Impact factor: 5.590

Review 9.  Role of secretory phospholipase a(2) in CNS inflammation: implications in traumatic spinal cord injury.

Authors:  W Lee Titsworth; Nai-Kui Liu; Xiao-Ming Xu
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-06       Impact factor: 4.388

10.  Chronic NMDA administration to rats increases brain pro-apoptotic factors while decreasing anti-Apoptotic factors and causes cell death.

Authors:  Hyung-Wook Kim; Yunyoung C Chang; Mei Chen; Stanley I Rapoport; Jagadeesh S Rao
Journal:  BMC Neurosci       Date:  2009-09-28       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.